Shashikant B. Lele

1.5k total citations
29 papers, 699 citations indexed

About

Shashikant B. Lele is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Surgery. According to data from OpenAlex, Shashikant B. Lele has authored 29 papers receiving a total of 699 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Reproductive Medicine, 9 papers in Obstetrics and Gynecology and 6 papers in Surgery. Recurrent topics in Shashikant B. Lele's work include Ovarian cancer diagnosis and treatment (24 papers), Reproductive Biology and Fertility (6 papers) and Endometrial and Cervical Cancer Treatments (6 papers). Shashikant B. Lele is often cited by papers focused on Ovarian cancer diagnosis and treatment (24 papers), Reproductive Biology and Fertility (6 papers) and Endometrial and Cervical Cancer Treatments (6 papers). Shashikant B. Lele collaborates with scholars based in United States and Netherlands. Shashikant B. Lele's co-authors include M. Steven Piver, Joseph J. Barlow, Trudy R. Baker, Lawrence J. Emrich, Y. Tsukada, Leslie E. Blumenson, David L. Marchetti, Annelies Hartman, John H. Malfetano and Roger L. Priore and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and American Journal of Obstetrics and Gynecology.

In The Last Decade

Shashikant B. Lele

28 papers receiving 669 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shashikant B. Lele United States 13 531 322 255 123 118 29 699
H D Homesley United States 9 468 0.9× 218 0.7× 335 1.3× 55 0.4× 163 1.4× 12 611
Antonella Villa Italy 18 626 1.2× 365 1.1× 283 1.1× 67 0.5× 171 1.4× 42 820
Griffiths Ct 6 812 1.5× 340 1.1× 583 2.3× 133 1.1× 141 1.2× 6 926
Alton V. Hallum United States 14 397 0.7× 339 1.1× 311 1.2× 155 1.3× 88 0.7× 25 677
N. Finkler United States 13 376 0.7× 154 0.5× 224 0.9× 166 1.3× 197 1.7× 30 713
William J. Hoskins United States 8 300 0.6× 294 0.9× 249 1.0× 171 1.4× 89 0.8× 8 565
Jonathan Herod United Kingdom 7 1.0k 1.9× 576 1.8× 623 2.4× 103 0.8× 232 2.0× 8 1.2k
J. Mould United Kingdom 14 168 0.3× 217 0.7× 183 0.7× 58 0.5× 118 1.0× 27 445
Joan E. Woodward United States 11 188 0.4× 230 0.7× 112 0.4× 54 0.4× 112 0.9× 12 454
Tito Lopes United Kingdom 5 938 1.8× 491 1.5× 615 2.4× 96 0.8× 206 1.7× 7 1.0k

Countries citing papers authored by Shashikant B. Lele

Since Specialization
Citations

This map shows the geographic impact of Shashikant B. Lele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shashikant B. Lele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shashikant B. Lele more than expected).

Fields of papers citing papers by Shashikant B. Lele

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shashikant B. Lele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shashikant B. Lele. The network helps show where Shashikant B. Lele may publish in the future.

Co-authorship network of co-authors of Shashikant B. Lele

This figure shows the co-authorship network connecting the top 25 collaborators of Shashikant B. Lele. A scholar is included among the top collaborators of Shashikant B. Lele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shashikant B. Lele. Shashikant B. Lele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ioffe, Olga B., Kay J. Park, David G. Mutch, et al.. (2020). Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. UNC Libraries. 2 indexed citations
2.
Starbuck, Kristen, Kevin H. Eng, Kayla Morrell, et al.. (2018). Prognostic impact of adjuvant chemotherapy treatment delays for ovarian cancer: A cohort study. Gynecologic Oncology. 149. 127–128.
3.
Starbuck, Kristen, Kayla Morrell, Emese Zsíros, et al.. (2018). Proton pump inhibitor use during chemotherapy for platinum-resistant or platinum-refractory ovarian cancer improves overall survival. Gynecologic Oncology. 149. 68–68. 3 indexed citations
4.
5.
Szender, J. Brian & Shashikant B. Lele. (2015). Fallopian Tube Ligation or Salpingectomy as Means for Reducing Risk of Ovarian Cancer. The AMA Journal of Ethic. 17(9). 843–848. 5 indexed citations
6.
Wei, Wei, Mark F. Brady, Vinod Vathipadiekal, et al.. (2015). Abstract PR05: An assessment of the prognostic and predictive associations of 13 angiogenic biomarkers in women with newly diagnosed advanced ovarian cancer treated with chemotherapy with or without bevacizumab. Molecular Cancer Therapeutics. 14(12_Supplement_1). PR05–PR05. 2 indexed citations
7.
Lele, Shashikant B., et al.. (2014). Oxaliplatin Is a Safe Alternative Option for Patients With Recurrent Gynecologic Cancers After Hypersensitivity Reaction to Carboplatin. International Journal of Gynecological Cancer. 25(1). 42–48. 18 indexed citations
8.
Dewdney, Summer, Nora T. Kizer, Abegail A. Andaya, et al.. (2012). Uterine Serous Carcinoma: Increased Familial Risk for Lynch-Associated Malignancies. Cancer Prevention Research. 5(3). 435–443. 17 indexed citations
9.
Marchetti, David L., et al.. (1993). Treatment of Advanced Ovarian Carcinoma in the Elderly. Gynecologic Oncology. 49(1). 86–91. 33 indexed citations
10.
Piver, M. Steven, John H. Malfetano, Trudy R. Baker, Shashikant B. Lele, & David L. Marchetti. (1989). Adjuvant cisplatin-based chemotherapy for stage I ovarian adenocarcinoma: A preliminary report. Gynecologic Oncology. 35(1). 69–72. 18 indexed citations
11.
Lele, Shashikant B. & M. Steven Piver. (1989). Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma. Gynecologic Oncology. 33(1). 6–8. 27 indexed citations
12.
Piver, M. Steven, et al.. (1988). The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma.. Journal of Clinical Oncology. 6(6). 983–989. 129 indexed citations
13.
Baker, Trudy R., M.Steven Piver, Shashikant B. Lele, & Yoshiaki Tsukada. (1988). Stage I uterine adenosarcoma: A report of six cases. Journal of Surgical Oncology. 37(2). 128–132. 11 indexed citations
14.
15.
Lele, Shashikant B., et al.. (1988). Five and Ten Year Estimated Survival and Disease-Free Rates after Intraperitoneal Chromic Phosphate; Stage I Ovarian Adenocarcinoma. American Journal of Clinical Oncology. 11(5). 515–519. 10 indexed citations
16.
Lele, Shashikant B. & Steven Piver. (1986). Interval Laparoscopy as Predictor of Response to Chemotherapy in Ovarian Carcinoma. Obstetrics and Gynecology. 68(3). 345–347. 9 indexed citations
17.
Piver, M. Steven, Shashikant B. Lele, Joseph J. Barlow, & Leslie E. Blumenson. (1982). Paraaortic lymph node evaluation in stage I endometrial carcinoma.. PubMed. 59(1). 97–100. 72 indexed citations
18.
19.
Lele, Shashikant B., M. Steven Piver, & Joseph J. Barlow. (1980). Chemotherapy in management of mixed mesodermal tumors of the ovary. Gynecologic Oncology. 10(3). 298–302. 18 indexed citations
20.
Piver, M. Steven, Joseph J. Barlow, & Shashikant B. Lele. (1978). Incidence of subclinical metastasis in stage I and II ovarian carcinoma.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 52(1). 100–4. 136 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H D Homesley Breakdown of academic impact, for papers by Antonella Villa Breakdown of academic impact, for papers by Griffiths Ct Breakdown of academic impact, for papers by Alton V. Hallum Breakdown of academic impact, for papers by N. Finkler Breakdown of academic impact, for papers by William J. Hoskins Breakdown of academic impact, for papers by Jonathan Herod Breakdown of academic impact, for papers by J. Mould Breakdown of academic impact, for papers by Joan E. Woodward Breakdown of academic impact, for papers by Tito Lopes
Rankless by CCL
2026